ARMP
Armata Pharmaceuticals, Inc.
Price Chart
Latest Quote
$7.08
+0.02 (+0.28%)
Current Price
| Previous Close | $7.06 |
| Open | $7.12 |
| Day High | $7.20 |
| Day Low | $6.94 |
| Volume | 15,265 |
Stock Information
| Shares Outstanding | 36.71M |
| Total Debt | $373.67M |
| Cash Equivalents | $4.75M |
| Revenue | $5.20M |
| Net Income | $-282.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $259.91M |
| EPS (TTM) | $-7.78 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $617.74M |
| Sales | $5.20M |
| Income | $-282.61M |
| Book/sh | $-8.50 |
| Cash/sh | $0.13 |
| Employees | 61 |
Financial Ratios
| Quick Ratio | 0.52 |
| Current Ratio | 0.64 |
Returns & Margins
| ROA | -25.32% |
| Gross Margin | -202.13% |
| Operating Margin | -1113.44% |
Ownership
| Insider Ownership | 68.53% |
| Institutional Ownership | 10.46% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.51 |
| P/S | 49.96 |
| P/B | -0.83 |
Analyst Data
| Recommendation | none |
| Target Price | $17.50 |
Technical Indicators
| SMA20 | $7.67 |
| SMA50 | $9.30 |
| SMA200 | $7.22 |
| RSI | 31.14 |
| ATR | 0.6507 |
| Shares Float | 11.32M |
| Short Float | 1.94% |
| Short Ratio | 2.65 |
| Rel Volume | 0.34 |
Performance History
| Week | -5.22% |
| Month | -16.31% |
| Quarter | -14.60% |
| 6 Months | +23.78% |
| YTD | +7.93% |
| Year | +280.65% |
| 3 Years | +398.59% |
| 5 Years | +54.25% |
| 10 Years | -97.11% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $7.08 | 21,300 |
| 2026-06-17 | $7.06 | 33,700 |
| 2026-06-16 | $6.79 | 152,400 |
| 2026-06-15 | $6.91 | 41,700 |
| 2026-06-12 | $7.58 | 77,900 |
| 2026-06-11 | $7.47 | 66,500 |
| 2026-06-10 | $7.56 | 29,600 |
| 2026-06-09 | $7.78 | 123,800 |
| 2026-06-08 | $7.57 | 24,600 |
| 2026-06-05 | $7.50 | 36,800 |
| 2026-06-04 | $7.69 | 32,500 |
| 2026-06-03 | $7.59 | 31,400 |
| 2026-06-02 | $7.92 | 37,000 |
| 2026-06-01 | $7.80 | 87,100 |
| 2026-05-29 | $8.17 | 96,400 |
| 2026-05-28 | $8.12 | 135,100 |
| 2026-05-27 | $7.97 | 66,800 |
| 2026-05-26 | $8.17 | 55,600 |
| 2026-05-22 | $8.36 | 41,800 |
| 2026-05-21 | $8.23 | 44,600 |
| 2026-05-20 | $8.12 | 67,400 |
| 2026-05-19 | $8.46 | 92,600 |
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
đ° Latest News
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
Insider Monkey âĸ 2026-03-02T15:23:00Z
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-12T22:25:02Z
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Zacks âĸ 2025-11-10T13:40:02Z
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-07T01:15:01Z
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Zacks âĸ 2025-11-03T23:05:03Z
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Zacks âĸ 2025-10-23T11:10:00Z
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
Zacks âĸ 2025-10-06T13:40:02Z
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-18T13:40:02Z
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-01T13:40:02Z
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
Zacks âĸ 2025-08-15T16:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $16,590,000 | $10,742,000 | $2,626,000 | $0 |
| Total Expenses | $31,222,000 | $42,436,000 | $40,890,000 | $36,946,000 |
| Other Income Expense | $-126,375,000 | $33,565,000 | $-25,708,000 | - |
| Other Non Operating Income Expenses | $-120,963,000 | $31,399,000 | $-21,845,000 | - |
| Net Non Operating Interest Income Expense | $-16,202,000 | $-10,045,000 | $-2,447,000 | $29,000 |
| Interest Expense Non Operating | $16,590,000 | $10,742,000 | $2,626,000 | $0 |
| Operating Expense | $31,222,000 | $42,436,000 | $40,890,000 | $36,946,000 |
| Other Operating Expenses | $-4,904,000 | $-5,174,000 | $-4,529,000 | $-5,508,000 |
| General And Administrative Expense | $12,409,000 | $13,184,000 | $11,649,000 | $7,437,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Net Interest Income | $-16,202,000 | $-10,045,000 | $-2,447,000 | $29,000 |
| Interest Income | $388,000 | $697,000 | $179,000 | $29,000 |
| Normalized Income | $-168,387,000 | $-21,082,000 | $-65,182,000 | $-36,917,000 |
| Net Income From Continuing And Discontinued Operation | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Total Operating Income As Reported | $-36,634,000 | $-42,436,000 | $-40,890,000 | $-36,946,000 |
| Net Income Common Stockholders | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Net Income | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Net Income Including Noncontrolling Interests | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Net Income Continuous Operations | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Pretax Income | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Special Income Charges | $-5,412,000 | $2,166,000 | $-3,863,000 | $0 |
| Interest Income Non Operating | $388,000 | $697,000 | $179,000 | $29,000 |
| Operating Income | $-31,222,000 | $-42,436,000 | $-40,890,000 | $-36,946,000 |
| Per Share | ||||
| Diluted EPS | $-4.80 | $-0.89 | $-1.91 | $-1.08 |
| Basic EPS | $-4.80 | $-0.52 | $-1.91 | $-1.08 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-150,266,000 | $-9,015,000 | $-61,584,000 | $-36,025,000 |
| Total Unusual Items | $-5,412,000 | $2,166,000 | $-3,863,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-5,412,000 | $2,166,000 | $-3,863,000 | $0 |
| Reconciled Depreciation | $1,531,000 | $1,325,000 | $972,000 | $892,000 |
| EBITDA (Bullshit earnings) | $-155,678,000 | $-6,849,000 | $-65,447,000 | $-36,025,000 |
| EBIT | $-157,209,000 | $-8,174,000 | $-66,419,000 | $-36,917,000 |
| Diluted Average Shares | $36,239,253 | $59,059,971 | $36,075,555 | $34,294,124 |
| Basic Average Shares | $36,239,253 | $36,160,848 | $36,075,555 | $34,294,124 |
| Diluted NI Availto Com Stockholders | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Write Off | $5,412,000 | $0 | - | - |
| Research And Development | $23,717,000 | $34,426,000 | $33,770,000 | $35,017,000 |
| Selling General And Administration | $12,409,000 | $13,184,000 | $11,649,000 | $7,437,000 |
| Other Gand A | $12,409,000 | $13,184,000 | $11,649,000 | $7,437,000 |
| Other Special Charges | - | $-2,166,000 | $3,863,000 | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-232,342,000 | $-61,765,000 | $-45,811,000 | $22,334,000 |
| Total Assets | $76,882,000 | $86,437,000 | $98,363,000 | $95,834,000 |
| Total Non Current Assets | $66,214,000 | $75,129,000 | $79,212,000 | $68,787,000 |
| Other Non Current Assets | $6,363,000 | $6,455,000 | $8,190,000 | $8,389,000 |
| Goodwill And Other Intangible Assets | $13,746,000 | $13,746,000 | $13,746,000 | $13,746,000 |
| Other Intangible Assets | $10,256,000 | $10,256,000 | $10,256,000 | $10,256,000 |
| Current Assets | $10,668,000 | $11,308,000 | $19,151,000 | $27,047,000 |
| Other Current Assets | $1,508,000 | $1,273,000 | $2,265,000 | $3,664,000 |
| Receivables | $472,000 | $744,000 | $3,363,000 | $8,531,000 |
| Other Receivables | $472,000 | $744,000 | $3,363,000 | $8,531,000 |
| Cash Cash Equivalents And Short Term Investments | $8,688,000 | $9,291,000 | $13,523,000 | $14,852,000 |
| Cash And Cash Equivalents | $8,688,000 | $9,291,000 | $13,523,000 | $14,852,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $248,233,000 | $85,099,000 | $68,784,000 | - |
| Total Debt | $288,018,000 | $126,515,000 | $120,371,000 | $48,815,000 |
| Long Term Debt And Capital Lease Obligation | $283,454,000 | $83,130,000 | $110,890,000 | $31,804,000 |
| Long Term Debt | $256,921,000 | $55,436,000 | $82,307,000 | - |
| Current Debt And Capital Lease Obligation | $4,564,000 | $43,385,000 | $9,481,000 | $17,011,000 |
| Current Debt | - | $38,954,000 | - | - |
| Other Current Borrowings | - | $38,954,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $295,478,000 | $134,456,000 | $130,428,000 | $59,754,000 |
| Total Non Current Liabilities Net Minority Interest | $286,531,000 | $86,207,000 | $113,967,000 | $34,881,000 |
| Non Current Deferred Liabilities | $3,077,000 | $3,077,000 | $3,077,000 | $3,077,000 |
| Non Current Deferred Taxes Liabilities | $3,077,000 | $3,077,000 | $3,077,000 | $3,077,000 |
| Current Liabilities | $8,947,000 | $48,249,000 | $16,461,000 | $24,873,000 |
| Other Current Liabilities | $487,000 | $529,000 | $523,000 | - |
| Payables And Accrued Expenses | $1,705,000 | $2,055,000 | $5,689,000 | $6,034,000 |
| Payables | $921,000 | $766,000 | $1,585,000 | $1,678,000 |
| Accounts Payable | $921,000 | $766,000 | $1,585,000 | $1,678,000 |
| Current Deferred Liabilities | - | - | - | - |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-218,596,000 | $-48,019,000 | $-32,065,000 | $36,080,000 |
| Total Equity Gross Minority Interest | $-218,596,000 | $-48,019,000 | $-32,065,000 | $36,080,000 |
| Stockholders Equity | $-218,596,000 | $-48,019,000 | $-32,065,000 | $36,080,000 |
| Retained Earnings | $-501,534,000 | $-327,735,000 | $-308,819,000 | $-239,774,000 |
| Other | ||||
| Ordinary Shares Number | $36,431,444 | $36,183,067 | $36,122,932 | $36,144,706 |
| Share Issued | $36,431,444 | $36,183,067 | $36,122,932 | $36,144,706 |
| Tangible Book Value | $-232,342,000 | $-61,765,000 | $-45,811,000 | $22,334,000 |
| Invested Capital | $38,325,000 | $46,371,000 | $50,242,000 | $36,080,000 |
| Working Capital | $1,721,000 | $-36,941,000 | $2,690,000 | $2,174,000 |
| Capital Lease Obligations | $31,097,000 | $32,125,000 | $38,064,000 | $48,815,000 |
| Total Capitalization | $38,325,000 | $7,417,000 | $50,242,000 | $36,080,000 |
| Additional Paid In Capital | $282,574,000 | $279,354,000 | $276,393,000 | $275,493,000 |
| Capital Stock | $364,000 | $362,000 | $361,000 | $361,000 |
| Common Stock | $364,000 | $362,000 | $361,000 | $361,000 |
| Long Term Capital Lease Obligation | $26,533,000 | $27,694,000 | $28,583,000 | $31,804,000 |
| Current Capital Lease Obligation | $4,564,000 | $4,431,000 | $9,481,000 | $17,011,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,191,000 | $2,280,000 | $768,000 | $1,828,000 |
| Current Accrued Expenses | $784,000 | $1,289,000 | $4,104,000 | $4,356,000 |
| Goodwill | $3,490,000 | $3,490,000 | $3,490,000 | $3,490,000 |
| Net PPE | $46,105,000 | $54,928,000 | $57,276,000 | $46,652,000 |
| Accumulated Depreciation | $-14,040,000 | $-13,146,000 | $-11,821,000 | $-11,103,000 |
| Gross PPE | $60,145,000 | $68,074,000 | $69,097,000 | $57,755,000 |
| Leases | $3,802,000 | $3,802,000 | $3,447,000 | $3,447,000 |
| Other Properties | $55,052,000 | $63,003,000 | $64,395,000 | $53,042,000 |
| Machinery Furniture Equipment | $1,291,000 | $1,269,000 | $1,255,000 | $1,266,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-26,305,000 | $-39,430,000 | $-55,567,000 | $-34,692,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-25,763,000 | $-37,551,000 | $-47,423,000 | $-32,481,000 |
| Cash Flow From Continuing Operating Activities | $-25,763,000 | $-37,551,000 | $-47,423,000 | $-32,481,000 |
| Operating Gains Losses | - | $-2,166,000 | $3,944,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-542,000 | $-1,879,000 | $-8,144,000 | $-2,211,000 |
| Investing Cash Flow | $-542,000 | $-1,879,000 | $-8,134,000 | $-2,211,000 |
| Cash Flow From Continuing Investing Activities | $-542,000 | $-1,879,000 | $-8,134,000 | $-2,211,000 |
| Financing Activities | ||||
| Financing Cash Flow | $25,612,000 | $34,958,000 | $53,988,000 | $44,016,000 |
| Cash Flow From Continuing Financing Activities | $25,612,000 | $34,958,000 | $53,988,000 | $44,016,000 |
| Net Other Financing Charges | $-46,000 | $-61,000 | $-43,000 | $-500,000 |
| Issuance Of Capital Stock | - | - | $0 | $44,391,000 |
| Net Common Stock Issuance | - | - | $0 | $44,391,000 |
| Common Stock Issuance | - | - | $0 | $44,391,000 |
| Other | ||||
| Issuance Of Debt | $25,000,000 | $34,889,000 | $54,026,000 | $0 |
| End Cash Position | $14,078,000 | $14,771,000 | $19,243,000 | $20,812,000 |
| Beginning Cash Position | $14,771,000 | $19,243,000 | $20,812,000 | $11,488,000 |
| Changes In Cash | $-693,000 | $-4,472,000 | $-1,569,000 | $9,324,000 |
| Proceeds From Stock Option Exercised | $658,000 | $130,000 | $5,000 | $125,000 |
| Net Issuance Payments Of Debt | $25,000,000 | $34,889,000 | $54,026,000 | $0 |
| Net Long Term Debt Issuance | $25,000,000 | $34,889,000 | $54,026,000 | $0 |
| Long Term Debt Issuance | $25,000,000 | $34,889,000 | $54,026,000 | $0 |
| Net PPE Purchase And Sale | $-542,000 | $-1,879,000 | $-8,134,000 | $-2,211,000 |
| Purchase Of PPE | $-542,000 | $-1,879,000 | $-8,144,000 | $-2,211,000 |
| Change In Working Capital | $-1,412,000 | $-2,099,000 | $-9,646,000 | $439,000 |
| Change In Other Current Liabilities | $-1,028,000 | $-4,962,000 | $-13,451,000 | $3,643,000 |
| Change In Payables And Accrued Expense | $-423,000 | $-2,243,000 | $-1,021,000 | $4,458,000 |
| Change In Accrued Expense | $-89,000 | $1,512,000 | $-1,060,000 | $793,000 |
| Change In Payable | $-334,000 | $-3,755,000 | $39,000 | $3,665,000 |
| Change In Account Payable | $-334,000 | $-3,755,000 | $39,000 | $3,665,000 |
| Change In Prepaid Assets | $39,000 | $5,106,000 | $4,826,000 | $-7,662,000 |
| Other Non Cash Items | $139,895,000 | $-18,588,000 | $25,414,000 | - |
| Stock Based Compensation | $2,610,000 | $2,893,000 | $938,000 | $3,105,000 |
| Asset Impairment Charge | $5,412,000 | - | - | - |
| Depreciation Amortization Depletion | $1,531,000 | $1,325,000 | $972,000 | $892,000 |
| Depreciation And Amortization | $1,531,000 | $1,325,000 | $972,000 | $892,000 |
| Depreciation | $1,531,000 | $1,325,000 | - | $892,000 |
| Net Income From Continuing Operations | $-173,799,000 | $-18,916,000 | $-69,045,000 | $-36,917,000 |
| Sale Of PPE | - | $0 | $10,000 | $0 |
| Gain Loss On Sale Of PPE | - | $0 | $81,000 | $0 |
| Interest Paid Cfo | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $3,643,000 |
| Change In Receivables | - | - | - | $1,053,000 |
Fetched: 2026-06-16